Free Trial

Valneva (VALN) Competitors

$8.52
-0.09 (-1.05%)
(As of 05/24/2024 ET)

VALN vs. ADPT, CABA, ITOS, ALEC, EXAI, ALLO, TSHA, FATE, EDIT, and HLVX

Should you be buying Valneva stock or one of its competitors? The main competitors of Valneva include Adaptive Biotechnologies (ADPT), Cabaletta Bio (CABA), iTeos Therapeutics (ITOS), Alector (ALEC), Exscientia (EXAI), Allogene Therapeutics (ALLO), Taysha Gene Therapies (TSHA), Fate Therapeutics (FATE), Editas Medicine (EDIT), and HilleVax (HLVX). These companies are all part of the "biological products, except diagnostic" industry.

Valneva vs.

Adaptive Biotechnologies (NASDAQ:ADPT) and Valneva (NASDAQ:VALN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, community ranking, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.

99.2% of Adaptive Biotechnologies shares are owned by institutional investors. Comparatively, 11.4% of Valneva shares are owned by institutional investors. 6.2% of Adaptive Biotechnologies shares are owned by company insiders. Comparatively, 14.9% of Valneva shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Adaptive Biotechnologies had 1 more articles in the media than Valneva. MarketBeat recorded 9 mentions for Adaptive Biotechnologies and 8 mentions for Valneva. Valneva's average media sentiment score of 0.66 beat Adaptive Biotechnologies' score of 0.44 indicating that Adaptive Biotechnologies is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Adaptive Biotechnologies
5 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Valneva
1 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Adaptive Biotechnologies received 67 more outperform votes than Valneva when rated by MarketBeat users. Likewise, 56.52% of users gave Adaptive Biotechnologies an outperform vote while only 53.33% of users gave Valneva an outperform vote.

CompanyUnderperformOutperform
Adaptive BiotechnologiesOutperform Votes
91
56.52%
Underperform Votes
70
43.48%
ValnevaOutperform Votes
24
53.33%
Underperform Votes
21
46.67%

Adaptive Biotechnologies currently has a consensus price target of $6.80, suggesting a potential upside of 97.67%. Valneva has a consensus price target of $21.67, suggesting a potential upside of 154.30%. Given Adaptive Biotechnologies' stronger consensus rating and higher probable upside, analysts plainly believe Valneva is more favorable than Adaptive Biotechnologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adaptive Biotechnologies
0 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.67
Valneva
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Adaptive Biotechnologies has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500. Comparatively, Valneva has a beta of 2.22, meaning that its share price is 122% more volatile than the S&P 500.

Valneva has lower revenue, but higher earnings than Adaptive Biotechnologies. Valneva is trading at a lower price-to-earnings ratio than Adaptive Biotechnologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adaptive Biotechnologies$170.28M2.98-$225.25M-$1.49-2.31
Valneva$165.52M3.58-$109.78M-$0.41-20.78

Valneva has a net margin of -15.88% compared to Valneva's net margin of -123.24%. Adaptive Biotechnologies' return on equity of -14.56% beat Valneva's return on equity.

Company Net Margins Return on Equity Return on Assets
Adaptive Biotechnologies-123.24% -56.58% -27.45%
Valneva -15.88%-14.56%-4.78%

Summary

Valneva beats Adaptive Biotechnologies on 10 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VALN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VALN vs. The Competition

MetricValnevaBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$593.33M$2.84B$5.20B$8.06B
Dividend YieldN/A2.61%2.83%3.93%
P/E Ratio-20.7827.22152.1518.19
Price / Sales3.58322.912,464.4379.80
Price / CashN/A190.1636.3031.61
Price / Book2.896.855.444.60
Net Income-$109.78M-$49.14M$106.24M$214.07M
7 Day Performance-3.67%-2.85%-1.33%-1.08%
1 Month Performance7.17%6.20%2.76%3.20%
1 Year Performance-30.28%3.20%3.39%7.84%

Valneva Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ADPT
Adaptive Biotechnologies
3.6599 of 5 stars
$3.96
+4.2%
$6.80
+71.7%
-50.6%$583.58M$174.50M-2.66709News Coverage
CABA
Cabaletta Bio
0.7869 of 5 stars
$11.23
-0.3%
$34.33
+205.7%
+6.3%$525.68MN/A-6.81101Analyst Forecast
ITOS
iTeos Therapeutics
2.1624 of 5 stars
$16.72
-1.8%
$31.00
+85.4%
+21.0%$601.42M$12.60M-4.42157Gap Up
High Trading Volume
ALEC
Alector
3.969 of 5 stars
$5.33
-1.1%
$14.00
+162.7%
-34.7%$513.76M$97.06M-3.86244Gap Up
EXAI
Exscientia
1.5158 of 5 stars
$4.99
+1.6%
$9.75
+95.4%
-41.9%$603.24M$25.60M-3.37483
ALLO
Allogene Therapeutics
3.2099 of 5 stars
$2.96
+2.1%
$13.50
+356.1%
-55.7%$505.33M$90,000.00-1.42232Analyst Forecast
Insider Buying
High Trading Volume
TSHA
Taysha Gene Therapies
1.9634 of 5 stars
$2.57
+7.1%
$6.88
+167.5%
+335.1%$480.64M$15.45M-3.8452Gap Up
FATE
Fate Therapeutics
4.53 of 5 stars
$4.22
+1.7%
$6.75
+60.0%
-34.1%$480.36M$63.53M-2.20181
EDIT
Editas Medicine
3.5758 of 5 stars
$5.68
-0.5%
$13.90
+144.7%
-40.4%$467.12M$78.12M-2.70265Gap Up
HLVX
HilleVax
3.1754 of 5 stars
$13.13
-3.7%
$30.67
+133.6%
-18.4%$652.82MN/A-3.9890News Coverage

Related Companies and Tools

This page (NASDAQ:VALN) was last updated on 5/25/2024 by MarketBeat.com Staff

From Our Partners